The present invention relates to methods and pharmaceutical compositions for the treatment of Alzheimers disease. In particular the present invention relates to a method of treating Alzheimers disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid molecule encoding for a polypeptide which is a soluble member of the APP (amyloid precursor protein) family.
